CCCC Q3 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-26.9% YoY

Gross Profit

$11M100.0% margin

Operating Income

-$34M-306.4% margin

Net Income

-$32M-286.4% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+73.8%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$265M

Total Liabilities

$111M

Stockholders' Equity

$154M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$15M	-26.9%
Gross Profit	$11M	$13M	-15.6%
Operating Income	-$34M	-$28M	-21.8%
Net Income	-$32M	-$25M	-30.4%